Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 Administered Orally to Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs SAM 315 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 04 Dec 2007 Status change from recruiting to completed.
- 27 Jul 2007 New trial record.